Guardant Health, Inc. GH
We take great care to ensure that the data presented and summarized in this overview for Guardant Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GH
View all-
Vanguard Group Inc Valley Forge, PA11.4MShares$290 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11MShares$279 Million0.01% of portfolio
-
Baillie Gifford & CO6.23MShares$158 Million0.1% of portfolio
-
Deep Track Capital, LP Greenwich, CT6MShares$152 Million4.09% of portfolio
-
Cadian Capital Management, LP New York, NY5.79MShares$147 Million4.28% of portfolio
-
Eventide Asset Management, LLC Boston, MA4.18MShares$106 Million1.39% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U04.11MShares$104 Million0.47% of portfolio
-
Capital International Investors Los Angeles, CA3.82MShares$96.9 Million0.02% of portfolio
-
Parkwood LLC Cleveland, OH2.8MShares$71 Million0.17% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.79MShares$70.8 Million0.01% of portfolio
Latest Institutional Activity in GH
Top Purchases
Top Sells
About GH
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Insider Transactions at GH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 15
2024
|
Myrtle S Potter Director |
BUY
Exercise of conversion of derivative security
|
Direct |
69
+0.89%
|
-
|
|
May 15
2024
|
Musa Tariq Director |
BUY
Exercise of conversion of derivative security
|
Direct |
250
+6.67%
|
-
|
|
May 15
2024
|
Darya Chudova Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,106
-6.74%
|
$77,650
$25.75 P/Share
|
|
May 15
2024
|
Darya Chudova Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,705
+15.88%
|
-
|
|
May 15
2024
|
Craig Eagle Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,327
-8.75%
|
$33,175
$25.75 P/Share
|
|
May 15
2024
|
Craig Eagle Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,717
+19.68%
|
-
|
|
May 04
2024
|
Meghan V. Joyce Director |
BUY
Exercise of conversion of derivative security
|
Direct |
66
+1.4%
|
-
|
|
May 03
2024
|
Helmy Eltoukhy Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200,000
+8.02%
|
$800,000
$4.18 P/Share
|
|
May 02
2024
|
Amir Ali Talasaz Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
283,830
+11.46%
|
$1,135,320
$4.18 P/Share
|
|
Apr 30
2024
|
Steve E. Krognes Director |
BUY
Exercise of conversion of derivative security
|
Direct |
154
+4.34%
|
-
|
|
Apr 15
2024
|
John G. Saia Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,809
-7.29%
|
$64,753
$17.06 P/Share
|
|
Apr 15
2024
|
John G. Saia Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,569
+21.06%
|
-
|
|
Apr 15
2024
|
Musa Tariq Director |
BUY
Exercise of conversion of derivative security
|
Direct |
249
+7.12%
|
-
|
|
Apr 15
2024
|
Myrtle S Potter Director |
BUY
Exercise of conversion of derivative security
|
Direct |
68
+0.89%
|
-
|
|
Apr 04
2024
|
Meghan V. Joyce Director |
BUY
Exercise of conversion of derivative security
|
Direct |
67
+1.44%
|
-
|
|
Apr 01
2024
|
John G. Saia Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
400
-1.79%
|
$8,000
$20.25 P/Share
|
|
Apr 01
2024
|
John G. Saia Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
974
+4.18%
|
-
|
|
Apr 01
2024
|
Craig Eagle Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
621
-5.14%
|
$12,420
$20.25 P/Share
|
|
Apr 01
2024
|
Craig Eagle Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,714
+12.43%
|
-
|
|
Apr 01
2024
|
Chris Freeman Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
531
-3.22%
|
$10,620
$20.25 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 665K shares |
|---|---|
| Open market or private purchase | 5.17K shares |
| Payment of exercise price or tax liability | 48.2K shares |
|---|---|
| Open market or private sale | 11K shares |